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Type 2 diabetes mellitus
A B S T R A C T
This observational study with a pre-post design, conducted in two Dutch primary healthcare centres, aimed to
evaluate the effect of a supervised walking programme in highly motivated individuals with or at risk for type 2
diabetes mellitus (T2DM). Those able and willing to walk at least 6 km, were invited for a 28-week walking
programme (February to August 2017), in which participants walked in groups, once weekly under supervision
of volunteer healthcare professionals. Changes in bodyweight, BMI, waist circumference, HbA1c, blood pressure,
well-being, health status and patient activation were analysed using paired t-tests and the Wilcoxon signed-rank
test. Fifty-six people were included (30 T2DM; 26 at risk), of whom 60.7% were female. Mean age was
60.6 years, median BMI 30.8 kg/m2 and mean systolic blood pressure 146.9mmHg. Participants with T2DM had
median HbA1c of 50.0 mmol/mol. Post-challenge, BMI had decreased to 29.7 kg/m2, and waist circumference
decreased 3.4 cm (95% CI 2.1–4.8), both p < 0.01. Systolic and diastolic blood pressure decreased significantly
(mean difference 6.5mmHg (95% CI 1.6–11.3, p=0.01) and 3.5 mmHg (95% CI 1.0–6.0, p < 0.01), respec-
tively). Participants with HbA1c> 53mmol/mol at baseline (n=8), had median decrease in HbA1c of
6.5 mmol/mol (p=0.03). Well-being, but not health status and patient activation, improved significantly. In
conclusion, in highly motivated individuals with or at risk for T2DM, this simple to implement and low-cost, but
intensive, volunteer-based supervised walking programme is favourable, and therefore, can be seen as an option
for clinical programs to implement to support highly motivated patients.
1. Introduction
The global prevalence of type 2 diabetes mellitus (T2DM) is rising
due to an aging population and the increasing prevalence of obesity and
physical inactivity, the latter two being major risk factors of T2DM
(World Health Organization, 2016; Statistics Netherlands (CBS), 2016).
Multiple randomised controlled trials (RCTs) of intensive interventions
have shown that T2DM can be prevented by changes in lifestyle
(Diabetes Prevention Program Research Group et al., 2002; Tuomilehto
et al., 2001), which in people with T2DM, can prevent or delay the
onset of macrovascular and microvascular complications (UK
Prospective Diabetes Study (UKPDS) Group, 1998; Coutinho et al.,
1999). In addition, a recent study in people with T2DM, delivered in the
primary care setting, showed that intensive weight management can
achieve remission of T2DM (Lean et al., 2017). Indeed, more intensive
programmes used in RCTs have great outcomes and therefore are highly
relevant for both people with and at risk for T2DM, but translation into
practical, affordable interventions delivered in a real-life setting has
shown to be less effective (Cardona-Morrell et al., 2010; Dunkley et al.,
2014) Besides, there does not seem to be an effective ‘one size fits all’
approach to engage people in lifestyle or self-management interven-
tions.
We developed a low-cost, volunteer-based, intervention as an option
to offer to people with multiple cardiovascular risk factors who were
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close to the top end of the full range of patient motivations and capa-
cities. Previous meta-analyses that studied the impact of walking pro-
grammes noted that walking could improve glycaemic control, body
mass index (BMI), and diastolic blood pressure (DBP) in people with
T2DM (Qiu et al., 2014). In sedentary but healthy adults, it also im-
proved systolic blood pressure (SBP) (Murtagh et al., 2015). The length
and the frequency of the walking sessions in included studies varied
from 20 to 120min and 2 to 7 times per week, respectively. Although
intensive lifestyle interventions to prevent and control diabetes have
shown to be cost-effective (≤$50.000/quality-adjusted life year)
(Jacobs-van der Bruggen et al., 2009; Li et al., 2010), our programme
likely reduces total costs due to the voluntary contribution of the
healthcare providers.
Since 2015, two primary healthcare centres in Nijkerk, in the
middle of the Netherlands, organise an annual supervised walking
programme for highly motivated individuals with T2DM and those at
risk for it, able to walk for 6 km once weekly as starting level. This six
months walking programme called the Nijkerk challenge (NC), ends
with a challenge week in which people walk six consecutive days. The
present study aims to evaluate the effect of this challenge on body-
weight, BMI, waist circumference, blood pressure, HbA1c, well-being,
health status and patient activation.
2. Methods
2.1. Study design and participants
This is an observational study with a pre-post study design with
28 weeks follow-up. Subjects were recruited from two primary health-
care centres in Nijkerk, providing care to about 1500 people with
T2DM. People with a T2DM diagnosis confirmed by International
Classification of Primary Care code T90.02 in the patient's electronic
medical record (EMR), and those considered at risk for T2DM by their
general practitioner (e.g. overweight, obesity, physical inactivity), were
assessed for eligibility. People with exercise-limiting co-morbidities not
able to walk 6 km at the start of the programme (e.g. old age, muscu-
loskeletal impairment or vascular disease of the lower extremities, vi-
sual impairment) were excluded from participation. All eligible people
were informed about the walking programme by letter and were invited
for an information session. People highly motivated, wanting to do a
significant walking challenge, and willing to participate in the NC re-
ceived a second letter in which they were informed about and asked to
participate in this particular study. Written informed consent was ob-
tained prior to participation from each participant. Ethical approval
was obtained by the Medical Ethical committee of the University
Medical Center Utrecht.
2.2. Nijkerk challenge programme
The Nijkerk challenge consists of a walking programme, in which
participants walked in groups, once weekly, under the supervision of
different volunteer healthcare professionals (physiotherapists, medical
practice assistants, podiatrists, dietitians, general practitioners and
sports coaches). Depending on their prior level of activity participants
started walking 6, 8 or 10 km. During the NC, participants could in-
crease their walking distance and intensity; and by the end of the study
all participants walked 10 km during each walking session. The walking
programme started on 18 February 2017. It ended with the challenge
week from 21 to 26 August 2017, in which the participants walked
approximately 15 km for six consecutive days. Participants walked for a
total of 28 weeks.
Although participants were encouraged to do more physical activity
outside of the one-time per week supervised walking, there were no
expectations for the participants to attain certain levels.
Apart from the walking programme, participants were able to at-
tend a diabetes education session and a cooking class. In addition,
individuals with T2DM were offered blood glucose self-monitoring
during one week at home two times, to obtain more insight into the
effects of their food choices, physical activity, and medication use on
glycaemic control.
2.3. Measurements
Prior to the Nijkerk challenge, on 13 February 2017, a measurement
session was organised for measuring bodyweight, length, waist cir-
cumference and blood pressure. Bodyweight, length and waist cir-
cumference were measured according to standardised procedures
(Nederlands Huisartsen Genootschap, 2012) using a digital balance, a
standard stadiometer and a measuring tape, respectively. Blood pres-
sure was measured using the Omron 6 comfort. After the Nijkerk
challenge, on 29 August 2017, the same aforementioned measurements
were taken. If a participant did not attend the measurement session, last
available measurements before the start and the end of the NC (with a
range of 2months prior or after), were extracted from the EMR; see
below.
Data extracted from the EMR were as followed: age, gender, dia-
betes duration, blood pressure, bodyweight, BMI, HbA1c, and pre-
scribed antihypertensive and blood glucose-lowering medication. Blood
pressure, BMI, HbA1c, and prescribed medication were extracted be-
tween two months before the start and two months after the NC.
Measurements closest to the start and end of the NC were used. Each
individual has his own HbA1c target value, based on the Dutch diabetes
guidelines (Rutten et al., 2013), which depends on age, medication use
and diabetes duration.
2.4. Patient reported outcome measures
Participants received online questionnaires before and after the NC.
Three validated questionnaires were used to assess well-being, health
status and patient activation. In addition, participants were asked for
their estimated attendance rate at the walking sessions and for their
attendance at the education session, cooking class and blood glucose
monitoring.
Well-being was measured using the 5-item WHO questionnaire
(WHO-5) covering items related to positive mood, vitality and general
interests (Topp et al., 2015; Psychiatric Center North Zealand, 2007).
Each item is rated on a 6-point Likert scale ranging from 0 ‘not present’
to 5 ‘constantly present’. The total score was multiplied by four to give a
final score ranging from 0 to 100, with lower scores indicating less well-
being.
Health status was measured with the EuroQol-visual analogue scale
(EQ-VAS) developed by The EuroQol Group (The EuroQol Group, 1990;
van Reenen & Janssen, 2015). It measures self-rated health on a ver-
tical, visual analogue scale, with 0 representing the worst health one
can imagine and 100 representing the best imaginable health.
The level of patient activation was measured by the 13-item patient
activation measure (PAM-13) (Hibbard et al., 2005; Rademakers et al.,
2012). It assesses an individual's knowledge, skills, and confidence for
managing one's health and healthcare. It uses a 5-point Likert scale
ranging from 1 ‘strongly disagree’ to 4 ‘strongly agree’ and 0 ‘not ap-
plicable’. A total score ranging from 0 to 100 was calculated, with
higher scores representing higher activation. Participants who an-
swered four or more questions with ‘not applicable’, as well as those
who answered all 13 questions with ‘strongly disagree’ or ‘strongly
agree’, were excluded. Subsequently, all participants with a valid PAM-
13 score were categorized into one of the four patient activation levels,
based on the Insignia Health guidelines, with level 1 being least acti-
vated and level 4 being most activated (Hibbard et al., 2005).
2.5. Statistical analyses
Descriptive statistics were used to describe the study population at
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baseline. Binary and categorical data are presented as frequencies and
percentages. Continuous variables are presented as means with stan-
dard deviations (SD) or as medians with interquartile range (IQR) for
skewed data. Paired t-tests were used to analyse pre-post challenge
differences for each variable. The Wilcoxon signed-rank test was used
for skewed paired data or small numbers. Analyses of weight, BMI,
waist circumference, blood pressure, well-being, health status and pa-
tient activation were performed in all participants. In addition, those of
weight, BMI, waist circumference, and blood pressure, were performed
in each group separately (at risk and T2DM). Analyses of blood pressure
and HbA1c were initially done for all participants. Subsequently, sen-
sitivity analyses were performed after excluding participants whose
antihypertensive medication or blood glucose-lowering medication
were changed during the NC. Analyses of HbA1c were also performed
after dividing participants in groups based on their HbA1c level at
baseline (HbA1c ≤53 or> 53mmol/mol). SPSS Analytical Software
version 21.0 (SPSS INC, Chicago, IL, USA) was used. A p-value below
0.05 was considered statistically significant.
3. Results
3.1. Participation and baseline characteristics
Of all invited people, only 75 participated in the NC, of whom 63
gave informed consent to participate in this study. A total of 56 parti-
cipants were included in this study, of whom 30 had T2DM and 26 were
at risk for it. During the NC six participants dropped out; five in the
T2DM group, one in the at-risk group (Fig. 1). The mean self-reported
attendance rate for the walking sessions was 79.5%. Of all participants
that filled in the questionnaires, 50% attended the cooking class, 55.6%
attended the education session and 47.4% of the participants with
T2DM monitored their glucose (Table 1).
Participants had a mean age of 60.6 (10.0) years and 60.7% were
female. Those with T2DM were older and more often male. Overall,
participants were typically obese and blood pressure was suboptimal at
baseline, despite an overall use of antihypertensive medication in
55.4% of the participants. Compared to participants in the at-risk
group, those with T2DM used antihypertensive medication more often.
With respect to BMI, waist circumference and blood pressure, both
groups were comparable at the start of the NC. Participants with T2DM
Individuals invited to participate in 
the Nijkerk challenge (n ~1200)
Consented to participate in current 
study (n=63)
Excluded (n=7)
-Failed inclusion criteria (n=1)
-No data available (n=4)
-Not registered at primary 
healthcare centers (n=2)




















Fig. 1. Participant enrolment flow chart of the Nijkerk challenge (Nijkerk, the Netherlands, February to August 2017).
Table 1
Self-reported attendance rate for the walking sessions, education session,







Distance starting level, n (%)
6 km 8 (22.2) 6 (35.3) 2 (10.5)
8 km 9 (25.0) 4 (23.5) 5 (26.3)
10 km 19 (52.8) 7 (41.2) 12 (63.2)
Proportions of walking sessions
attended, mean %
79.5 79.1 79.9
Education session, n (%) 20 (55.6) 8 (47.1) 12 (63.2)
Cooking class, n (%) 18 (50.0) 6 (35.3) 12 (63.2)
Glucose monitoring, n (%) N/A N/A 9 (47.4)
Continuous variables presented as means, dichotomous variables presented as
count (percentage). N, number of subjects. T2DM, type 2 diabetes mellitus. N/
A, not applicable.
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had a median HbA1c of 50 (Topp et al., 2015) mmol/mol at baseline,
but 33.3% had an HbA1c above their personal target value. The ma-
jority of the participants with T2DM was on metformin only (23.3%) or
a combination of metformin and sulfonylurea (30.0%), and 26.7% re-
ceived lifestyle advice only. At the start of the NC, participants with
T2DM experienced more well-being and a slightly better health status
compared to those at risk for it. About half of the participants had a
patient activation level 3 pre-challenge (Table 2).
3.2. Pre-post challenge differences
Pre- and post-challenge anthropometric measures and blood pres-
sure in the overall study population and in both groups separately are
presented in Table 3 and Table 4, respectively. The overall study po-
pulation showed significant improvements in body weight (median
decrease from 88 to 84 kg), BMI (median decrease from 30.7 to 29.7 kg/
m2), and waist circumference (mean difference 3.4 cm). Improvements
were larger in the at-risk group. Both SBP and DBP decreased sig-
nificantly (mean difference 6.5mmHg and 3.5mmHg, respectively),
although decrease in DBP was more pronounced in the T2DM group.
During the NC antihypertensive medication prescription was added in
four participants in the at-risk group and reduced in one participant in
the T2DM group. If these changes in antihypertensive medication were
taken into account, decreases in SBP and DBP became less pronounced
in the at-risk group (5.3 mmHg (p=0.10) and 1.8 mmHg (p=0.37),
respectively). In the T2DM group differences became more pronounced,
with a decrease of 7.4 mmHg in SBP (p=0.06) and 5.0 mmHg in DBP
(p=0.01).
Complete HbA1c data were available from 21 participants with
T2DM. Overall, no significant differences in median HbA1c were ob-
served. Subanalysis shows that those with an HbA1c ≤53mmol/mol at
the start of the NC (n=13) did not improve, whereas those with an
HbA1c above 53mmol/mol (n=8) improved from 64.0 (van Reenen &
Janssen, 2015) mmol/mol to 57.5 (Jacobs-van der Bruggen et al., 2009)
mmol/mol post-challenge (p=0.03). During the NC blood glucose-
lowering medication prescription was diminished in three participants
with an HbA1c ≤53mmol/mol and added in one with an HbA1c above
53mmol/mol. After excluding these participants, the decrease in
median HbA1c in the group with a higher HbA1c remained significant
(7.0 mmol/mol, p=0.04).
Only 20 participants filled in questionnaires both at the start and
post-challenge; 10 in each subgroup. Because of few data only results
for the overall study population are shown (Table 5). Participants ex-
perienced statistically significant more well-being.
4. Discussion
An easy to organise and low-cost 28-weeks supervised walking
programme significantly improved BMI, waist circumference, SBP and
DBP in a highly motivated study population that is able to walk for 6 km
once weekly as a starting level and wanting to do a significant walking
challenge. Furthermore, participants experienced significantly more
well-being and a better health status (non-significant) post-challenge.
Participants with T2DM whose HbA1c was>53mmol/mol, but not
those below that level, had a significant decrease in HbA1c post-chal-
lenge.
With respect to body composition, our findings are in agreement
with previous studies conducted in controlled settings in terms of di-
rection of effect. Qiu et al. (2014) and Murtagh et al. (2015) examined
in their meta-analyses the effect of walking on cardiovascular risk
factors in people with T2DM and sedentary but healthy participants,
respectively. They found significant improvements in bodyweight and
BMI, but with regard to the magnitude of the effect of a walking pro-
gramme on body composition, improvements were larger in our study
population. Although both meta-analyses included RCTs with a higher
frequency of walks per week (ranging from 2 to 7 times a week), both
supervised and non-supervised, our walking programme covered a
significant volume (i.e. distance). In abovementioned meta-analyses
duration of each walking session varied from 20 to 120min; average
duration is not given. Furthermore, we do not have any information
about the amount of unsupervised physical activity outside of the
walking programme, and neither about dietary outcomes, that both
might have contributed to the favourable effect found. Differences in
effect size may also be due to a lower BMI at baseline in the included
studies and a shorter walking programme. Moreover, weight loss in our
study population might be more since post-challenge measurements
were taken three days after the challenge-week in which participants
walked 15 km for six days consecutively. Maybe the highly selected
sample (highly motivated and able to walk 6 km once weekly at the
start) in our study population is the main trigger of our findings. If so, in
our opinion this does not affect their relevance. One size does not fit all,
but for those who want to walk in groups one day per week, the walking
programme seems a good option.
Table 2








Age, mean (SD), years 60.6 (10.0) 56.2 (9.2) 64.3 (9.2)
Women, n (%) 34 (60.7) 20 (76.9) 14 (46.7)
Anthropometric measures
Weight, median (IQR), kg 88.1 (20.3) 88.8 (26.6) 87.8 (18.4)
BMI, median (IQR), kg/m2 30.8 (5.4) 31.9 (6.2) 30.1 (5.0)
Waist circumference, mean
(SD), cm
108.7 (10.2)a 108.8 (10.7) 108.6 (9.9)b
Blood pressure, mean (SD),
mmHg
Systolic 146.9 (19.1) 146.5 (21.0) 147.2 (17.6)
Diastolic 89.9 (9.9) 91.3 (7.2) 88.8 (11.7)
Antihypertensive medication
use, n (%)
31 (55.4) 10 (38.5) 21 (70.0)
Diabetes factors N/A N/A
Duration of T2DM, mean (SD),
years
8.9 (5.4)
HbA1c, median (IQR) 50.0 (16)b
Blood glucose lowering
medication use, n (%)
Lifestyle advice only 8 (26.7)
Metformin only 7 (23.3)
Sulfonylurea only 1 (3.3)




sulfonylurea and other blood
glucose lowering medication
3 (10.0)
Insulin ± oral blood glucose
lowering medication
2 (6.7)
Questionnaires, median (IQR) n=45 n=23 n=22
WHO-5 68.0 (22) 64.0 (20) 72.0 (21)
EQ-VAS 74.0 (21) 74.0 (23) 78.00 (18)
PAM-13 55.6 (14.2)c 55.6 (9.6)d 55.6 (19.1)
Level of patient activation, n (%)
Level 1 9 (22.0) 3 (15.8) 6 (27.3)
Level 2 8 (19.5) 6 (31.6) 2 (9.1)
Level 3 19 (46.3) 9 (47.4) 10 (45.5)
Level 4 5 (12.2) 1 (5.3) 4 (18.2)
Continuous variables presented as means (SD) or medians (IQR), dichotomous
variables presented as count (percentage). N, number of subjects. SD, standard
deviation. IQR, interquartile range. T2DM, type 2 diabetes mellitus. BMI, body
mass index (calculated as weight in kilograms divided by height in meters
squared). N/A, not applicable. HbA1c, glycosylated haemoglobin A1c. WHO-5,
World Health Organization Five Well-Being Index. EQ-VAS, EuroQol Visual
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When compared to other lifestyle interventions, achieved weight
loss and decline in BMI were similar to results found in diabetes pre-
vention programmes in highly controlled settings (Diabetes Prevention
Program Research Group et al., 2002; Tuomilehto et al., 2001; Roumen
et al., 2008). Recently, Duijzer et al. (Duijzer et al., 2017) assessed the
effectiveness of the SLIMMER combined dietary and physical activity
lifestyle intervention in people at risk for T2DM in Dutch primary
healthcare. After 12months, the decrease in BMI was comparable to our
findings in a real-life setting. On the contrary, a one-year nurse-led
lifestyle program (Hesselink et al., 2015) and a cognitive behaviour
programme (Lakerveld et al., 2013), both performed in Dutch primary
healthcare, resulted in smaller changes in body composition.
The NC had high clinical impact on both SBP and DBP, and the
blood pressure decrease was larger than in the aforementioned meta-
analyses (Qiu et al., 2014; Murtagh et al., 2015). This may be due to the
higher blood pressure at baseline in our study population. Moreover,
since weight loss adds to the benefits of exercise alone (Neter et al.,
2003; Bacon et al., 2004; Franz et al., 2015), it is expected that the
higher magnitude of weight loss in our study contributed to the ob-
served effects. Other lifestyle intervention programmes in Dutch pa-
tients found larger decreases in DBP ranging from 2.8mmHg (Duijzer
et al., 2017) to 5.9 mmHg (Figueira et al., 2014), but smaller decreases
in SBP ranging from 2.8mmHg (Hesselink et al., 2015) to 4.7 mmHg
(Duijzer et al., 2017). Principally, the large decrease in SBP in our study
is favourable.
In contrast to the results of a previous meta-analysis (Qiu et al.,
2014), where an overall decline in HbA1c level of 0.58% (95% CI -0.93
to−0.23%) in supervised walking programmes was found, we were not
able to demonstrate such an improvement, most likely due to the fact
that on average participants with T2DM were well-controlled at the
start of the NC. This assumption is supported by the finding that gly-
caemic control did improve by 6.5 mmol/mol (~0.6%) in participants
with insufficient glycaemic control (HbA1c> 53mmol/mol), which is
in line with existing evidence that higher baseline HbA1c levels are
associated with greater reductions in HbA1c levels (Franz et al., 2015;
Reid et al., 2010; Guglani et al., 2014; Konig et al., 2009). Presumably,
the weight loss contributed to the observed decrease in HbA1c in par-
ticipants with insufficient glycaemic control, but previous studies have
also indicated that physical activity decreases the risk of diabetes
through mechanisms beyond weight loss alone (Hamman et al., 2006;
Laaksonen et al., 2005; Pan et al., 1997).
Recently, a cross-sectional study conducted in people with T2DM in
Dutch general practices, found a statistically significant, but not clini-
cally relevant, positive association between physical activity and well-
being (Hendriks et al., 2017). Although the former study is a cross-
sectional study, and therefore cause and effect cannot be determined,
our results showed that the NC significantly improved participant's
well-being, which is in line with other (Guglani et al., 2014; Kempf &
Table 3
Pre-challenge, post-challenge and changes in anthropometric measures and blood pressure in the overall study population of the Nijkerk challenge (February–August
2017).
N Pre-challenge Post-challenge Mean difference (95% CI) p-value
Weight, median, (IQR), kg 53 88.0 (20.0) 84.0 (22.4) ⎯ <0.01
BMI, median (IQR), kg/m2 53 30.7 (5.2) 29.7 (4.8) ⎯ <0.01
Waist circumference, mean (SD), cm 44 107.3 (9.5) 103.9 (9.8) 3.4 (2.1; 4.8) < 0.01
Blood pressure, mean (SD), mmHg
Systolic 54 147.3 (19.3) 140.9 (17.6) 6.5 (1.6; 11.3) 0.01
Diastolic 54 90.1 (9.9) 86.6 (9.0) 3.5 (1.0; 6.0) < 0.01
Variables presented as means (SD) or medians (IQR). If values are reported in means, p-values are calculated using the paired t-test; if values are given in medians, p-
values are calculated using the Wilcoxon Signed Rank test. N, number of subjects. SD, standard deviation. IQR, interquartile range. BMI, body mass index. CI,
confidence interval.
Table 4











Weight, median (IQR), kg 24 88.8 (24.6) 83.5 (23.3) ⎯ <0.01 29 87.5 (17.3) 85.0 (21.0) ⎯ 0.10
BMI, median (IQR), kg/m2 24 31.9 (5.8) 30.5 (3.6) ⎯ <0.01 29 30.0 (4.7) 28.7 (4.9) ⎯ 0.15
Waist circumference, mean (SD),
cm
24 108.3 (10.9) 104.4 (11.0) 3.9
(2.2; 5.6)
< 0.01 20 106.1 (7.7) 103.2 (8.4) 2.9
(0.5; 5.2)
0.02
Blood pressure, mean (SD),
mmHg
Systolic 25 146.9 (21.3) 140.4 (16.6) 6.5
(0.6; 12.4)
0.03 29 147.7 (17.7) 141.3 (18.6) 6.4
(−1.4; 14.2)
0.10
Diastolic 25 91.2 (7.4) 88.9 (9.0) 2.3
(−1.3; 5.8)
0.20 29 89.2 (11.7) 84.7 (8.7) 4.5
(0.8; 8.2)
0.02
Variables presented as means (SD) or medians (IQR). If values are reported in means, p-values are calculated using the paired t-test; if values are given in medians, p-
values are calculated using the Wilcoxon Signed Rank test. T2DM, type 2 diabetes mellitus. N, number of subjects. SD, standard deviation. IQR, interquartile range.
BMI, body mass index. CI, confidence interval.
Table 5
Pre-challenge, post-challenge and changes in questionnaire scores in the overall
study population of the Nijkerk challenge.
All participants (n=20)
Pre-challenge Post-challenge p-value
WHO-5 72.0 (20.0) 76.0 (12.0) 0.01
EQ-VAS 74.0 (23.0) 80.0 (15.8) 0.07
PAM-13a 55.6 (15.3) 58.1 (18.9) 0.37
Values are expressed in medians with interquartile range. P-value is calculated
using the Wilcoxon Signed Rank test. WHO-5, World Health Organization Five
Well-Being Index. EQ-VAS, EuroQol Visual Analogue scale. PAM-13, 13-item
Patient Activation Measure.
a n=18.
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Martin, 2013; Shenoy et al., 2010), but not all (Reid et al., 2010) studies
that examined the effect of exercise programmes on well-being. Im-
provements in health status reached significance, to a post-challenge
health status comparable to the overall Dutch population (Konig et al.,
2009). Significant improvements in health status, measured by EQ-VAS,
were reported of a 3-year lifestyle intervention programme performed
in primary healthcare (Eriksson et al., 2010). When compared to studies
that used the Short Form Health Survey (SF-36) as measure of physical
and mental health status, this concurs with the results of the IDES and
SLIMMER interventions (Duijzer et al., 2017; Nicolucci et al., 2011).
Well-being, physical health status and BMI are associated with pa-
tient activation and thereby influence diabetes control and self-man-
agement (Bos-Touwen et al., 2015; Hendriks et al., 2016). In the current
study, no significant increase in patient activation was found. Baseline
patient activation score was similar to those reported in two cross-
sectional studies in people with T2DM in the Netherlands (Bos-Touwen
et al., 2015; Hendriks et al., 2016). Many participants remained at
patient activation level 3 post-challenge, suggesting that these in-
dividuals are taking actions to self-manage their health (Rademakers
et al., 2012), although there is still room for improvement.
4.1. Study limitations and strengths
An important strength of our study is that it is conducted in a real-
life primary care setting. Besides, the walking programme is simple to
implement and low-cost, on the condition that a sufficient number of
volunteer health care professionals is available. Moreover, it evaluates
the effectiveness of supervised walking on various important outcome
measures. Despite the small number of people participating in this
study and a dropout rate of ~10%, both significant and clinical relevant
effects were found.
But, in interpreting our findings, several limitations need to be
considered. Since only a small number of people from the invited in-
dividuals agreed to participate, included participants are likely to be
more motivated for lifestyle interventions. The way of selecting parti-
cipants at risk for T2DM may also have caused selection bias. Because of
the highly selective group of motivated participants, generalizability of
the findings can be questioned. Although the outcomes are great in
magnitude, it is likely not ‘high impact’ as it may address only a small
proportion of affected or at-risk individuals and therefore its reduction
in community attributable risk is likely modest.
Potential confounders to the results of this study are the baseline
physical activity, the amount of physical activity people attained out-
side the walking programme, and the dietary habits. Since changes in
levels of physical activity outside the walking sessions and changes in
diet have not been assessed during the NC, it is unsure whether the
reported effects are only due to the walking programme itself. Since
post-challenge measurements are only taken three days after the chal-
lenge-week, we cannot provide information about long-term effects on
body composition.
5. Conclusion
In conclusion, in motivated individuals with T2DM and those at risk
for it, this study demonstrates that a once per week, intensive, su-
pervised walking programme, has favourable effects on body compo-
sition, blood pressure, HbA1c and well-being, and has potential to
improve health status. Such programme could hereby prevent T2DM,
and prevent or delay the onset of complications or induce remission,
although generalizability can be questioned because of the highly se-
lective group of motivated participants.
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